Press Releases

 
Press Releases
Date Title and Summary View
Aug 12, 2014 SALT LAKE CITY, Aug. 12, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced financial results for its fiscal fourth quarter and fiscal year ended June 30, 2014, provided an update on recent business highlights, and provided financial guidance for its fiscal year ending June 30, 2015. Revenue for the fiscal fourth quarter w...
Jul 30, 2014 SALT LAKE CITY, July 30, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fiscal fourth quarter and full year 2014 as well as provide financial guidance for fiscal year 2015 following the close of market on Tuesday, August 12, 2014. The Company also will host a conference ...
Jun 10, 2014 Vectra®DA Identified Patients in SWEFOT Clinical Study at Higher Risk of Joint Damage SALT LAKE CITY, June 10, 2014 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today announced that Vectra® DA data will be featured in eight posters at the 2014 European League Against Rheum...
Jun 9, 2014 SALT LAKE CITY, June 9, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that James Evans, chief financial officer of Myriad, has notified the Company of his intent to retire in order to attend to family health issues. To ensure a smooth transition, Evans will continue as the Company's CFO until a replacement can be foun...
Jun 3, 2014 SALT LAKE CITY, June 3, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO of Myriad, is scheduled to present at the 35th annual Goldman Sachs Global Healthcare Conference, at 10:40 a.m. Pacific on June 10, 2014, at the Terranea Resort in Rancho Palos Verdes, California. The pre...
Jun 2, 2014 SALT LAKE CITY, June 2, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) and leading cancer experts from the Memorial Sloan Kettering Cancer Center (MSKCC), Mayo Clinic, Abramson Cancer Center of the University of Pennsylvania and other laboratories are teaming up in a new partnership that will dramatically advance the understanding of ...
Jun 2, 2014 SALT LAKE CITY, June 2, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented results from a pivotal clinical validation study of the Myriad myPath™ Melanoma test at the 2014 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Ill. The Myriad myPath Melanoma test is a novel molecular test that accura...
Jun 2, 2014 SALT LAKE CITY, June 2, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented several clinical studies on the Myriad myRisk™ Hereditary Cancer test at the 2014 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois. Among the important new findings is that the myRisk test detects significantly ...
May 30, 2014 SALT LAKE CITY, May 30, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN), a global leader in molecular diagnostics, announced the presentation of new data at the American Society of Clinical Oncology (ASCO) meeting this week that supports the clinical efficacy of its BRACAnalysis CDx™ and HRD™ tests in predicting platinum ba...
May 20, 2014 SALT LAKE CITY, May 20, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented new data from a clinical validation study of Prolaris at the 2014 American Urological Association (AUA) Annual Meeting in Orlando, Fla.  The study is the largest validation study to date of any gene-based prognostic test in patients with prostate ca...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase